BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, May 28, 2026
Home » Blogs » BioWorld Perspectives » The Biotech Toddler Argument: “Chilling Effect on Innovation” Overplayed?

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld / Oncology

The Biotech Toddler Argument: “Chilling Effect on Innovation” Overplayed?

Nov. 18, 2011
By Trista Morrison

In last week’s issue of BioWorld Insight, our esteemed Washington editor Mari Serebrov wrote an article titled, “Shorter Exclusivity Could Carry a Hefty Price Tag.” In it, she quoted sources who are very concerned that reducing the current 12-year exclusivity for innovator biologics to seven years, as the president and a number of lawmakers have proposed, would be bad news for patients, payers and drug makers.

In the article, Mary Webster, a patent attorney with Nixon Peabody, said: "If you can't corner your market and recoup your costs, are you going to do it?"

And suddenly I had a flashback to negotiating with my three-year-old:

Me: “No you can’t have a cookie for dinner.”

Toddler: [crossing arms and stamping foot] “Fine, then I’m not going to eat anything for dinner.”

This scene has replayed itself in my head several times recently as I’ve written about biotech news – i.e. when gene patents are questioned, or reimbursement policies are debated, or drug importation gains traction, or the FDA shifts its stance on something. Each time, the industry’s response is to threaten that these moves will result in a “chilling effect on innovation” (translation: mess with us and we’ll stop making drugs).

Don’t get me wrong, I think the biotechnology industry deserves every advantage. But if biologics end up with seven years of exclusivity, do we really think companies will stop making them? Really? When biologics account for many of the top-selling drugs, each raking in multi-billions of dollars annually?

I worry that biopharma firms aren’t winning any points in the court of public opinion by stamping their feet and threatening to stop innovating every time something they don’t like gets put on the table. This approach certainly hasn’t worked for my toddler: When he threatens that he’s not going to eat dinner, I say, “fine, don’t eat” – and within minutes he’s seated at the table, munching away on his veggies.

You know what did work, though? When he said, “What if I eat a good dinner? Then can I have a cookie?” Negotiation is a fact of life – everybody has to give and take. My three-year old figured it out. Maybe it’s time for the industry to follow suit.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 27, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 26, 2026
  • Microscopy of a cross-section of mouse skin containing melanoma tumors

    Researchers identify innate immune barrier against melanoma

    BioWorld
    Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live...
  • Cavalon Therapeutics and Northwestern patent new Cav1.3 blockers

    BioWorld Science
    Cavalon Therapeutics Inc. and Northwestern University have disclosed new voltage-gated calcium channel Cav1.3 blockers potentially useful for the treatment of...
  • In the clinic for May 26, 2026

    BioWorld
    Clinical updates for biopharma and med tech, including data readouts and publications: 858, A2 Biotherapeutics, AC Immune, Agendia, Agenus, Aktis, Ascentage,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing